RYTM

Research · Sep 3, 2026

[RYTM] Rhythm Pharmaceuticals Thesis 2026: An MC4R Drug Expands From Ultra-Rare Obesity Toward a Bigger Market

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is a Boston, Massachusetts-headquartered commercial-stage biopharmaceutical company dedicated to rare neuroendocrine diseases — specifically disorders of the melanocortin-4 receptor (MC4R) pathway, the brain circuit (hypothalamic, leptin-melanocortin) that regulates hunger and energy balance; when this pathway is disrupted — by rare genetic mutations upstream of MC4R, or by physical damage to the hypothalamus — patients suffer hyperphagia (an unrelenting, pathological hunger) and severe, early-onset obesity. Rhythm's lead and only marketed product is IMCIVREE (setmelanotide) — a peptide MC4R agonist (once-daily subcutaneous injection) that activates the receptor downstream of the genetic defect — first FDA-approved in 2020 for obesity and hunger control in patients with POMC, PCSK1 or LEPR deficiency (ultra-rare monogenic obesity), then expanded in 2022 to Bardet-Biedl syndrome (BBS, a rare ciliopathy), with EU and other approvals following; the franchise is now expanding toward acquired hypothalamic obesity — obesity caused by damage to the hypothalamus from craniopharyngioma or other brain tumors, their surgical resection, or radiation — a substantially larger patient population, supported by a positive Phase 3 trial (the TRANSCEND study) and a regulatory filing under FDA review. Behind setmelanotide, Rhythm is building a next-generation MC4R pipeline: bivamelagon (an oral, once-daily small-molecule MC4R agonist in-licensed from LG Chem) and RM-718 (a weekly subcutaneous MC4R agonist) — aimed at better convenience and a broader population — plus exploration of additional MC4R-pathway indications. RYTM enters FY2026 with FY2025 net product revenue selected various aggregate ~$150-280M (rapid growth, entirely IMCIVREE), an aggregate net loss ~$(150)-(280)M (the commercial build for the AHO launch plus the bivamelagon/RM-718 programs) and a cash/equivalents/short-term-investments position ~$250-450M+ implying a runway extending roughly into 2026-2027, under Chairman, President & CEO David Meeker (~5+ year tenure since 2020; a former Genzyme/Sanofi rare-disease leader). The first thesis pillar is the IMCIVREE (setmelanotide) commercial franchise — the business (selected various aggregate the entirety of revenue, growing fast) and a classic rare-disease 'land and expand': today's base is rare genetic obesity — setmelanotide approved and launched for POMC/PCSK1/LEPR deficiency (the original ultra-rare monogenic indications) and Bardet-Biedl syndrome, with prescribing physicians (pediatric endocrinologists, geneticists, obesity specialists) identifying patients often through genetic-testing programs Rhythm supports (it sponsors panels and registries — diagnosis being the bottleneck), revenue growing as more patients are identified, started and retained (compliance with a daily injection a watch item) and as ex-US markets (EU, others) ramp post-approval and reimbursement; the expansion is acquired hypothalamic obesity (AHO) — the big near-term opportunity — patients who develop intractable obesity and hyperphagia after hypothalamic damage (most commonly from craniopharyngioma and its treatment) have few options, Rhythm ran the TRANSCEND Phase 3 trial of setmelanotide in AHO with positive results (meaningful weight reduction and hunger improvement) and has a regulatory filing under FDA review (with EU and other filings following), pointing to a potential approval and launch into a population estimated several times larger than the genetic-obesity base, with a more readily identifiable patient (already in the neuro-oncology/endocrinology system); FY2025 dynamics are genetic-obesity revenue growing on patient adds and ex-US ramp, the AHO filing progressing toward an FDA decision, commercial investment ahead of the AHO launch, and pricing holding (a high-priced rare-disease therapy); FY2026 catalyst is the AHO FDA decision and launch ramp (the single biggest value driver), continued genetic-obesity growth, ex-US expansion, and progress toward operating breakeven as revenue scales over the cost base; risks/competitors are an AHO regulatory setback or a slow launch, reimbursement pushback on a costly drug in a now-larger population, patient-identification and persistence challenges, and competition — within MC4R-pathway obesity Rhythm is essentially alone for now, but the broader obesity field (Novo Nordisk's and Eli Lilly's (LLY) GLP-1/GIP drugs) is the backdrop, and while GLP-1s aren't approved/optimal for these hyperphagia-driven genetic/hypothalamic populations, payers and physicians will weigh options and other companies (e.g., those pursuing hypothalamic-obesity or rare-obesity programs) could emerge. The second pillar is the next-generation MC4R pipeline — meant to extend Rhythm's franchise beyond a daily injectable peptide: bivamelagon (LB54640) — an oral, once-daily small-molecule MC4R agonist in-licensed from LG Chem (Rhythm holds rights in most major markets) — is the headline pipeline asset (an oral drug would dramatically improve convenience versus daily setmelanotide injections, potentially expand the treatable population, and could be developed across the same indications and possibly broader hypothalamic-obesity or MC4R-pathway settings; it has moved through early/mid-stage clinical trials with encouraging signals and is advancing toward later-stage/pivotal development); RM-718 — a weekly subcutaneous MC4R agonist discovered by Rhythm — is the long-acting injectable option (weekly versus daily dosing is a big convenience step, and a longer-acting molecule may offer a better tolerability/exposure profile; it's in earlier clinical development); together they form a next-gen MC4R portfolio (oral for convenience/breadth, weekly injectable as an alternative) that, if successful, lets Rhythm offer the right modality for each patient and defend/extend the franchise as setmelanotide's exclusivity clock runs, with Rhythm also exploring additional MC4R-pathway indications; FY2025 dynamics are bivamelagon advancing through clinical development with data updates, RM-718 progressing in early trials, and the strategic logic (modality breadth + lifecycle extension) being built out; FY2026 catalyst is bivamelagon clinical data and pivotal-trial initiation/progress (the key pipeline event), RM-718 data, decisions on which indications to pursue with which molecule, and any business-development moves; risks/competitors are bivamelagon or RM-718 failing in trials (efficacy or safety/tolerability — MC4R agonism has known on-target effects like hyperpigmentation and, for some MC4R-class agents, cardiovascular signals to monitor), slower-than-hoped development, competition from any other MC4R or hypothalamic-obesity programs that emerge, and the possibility that the broad GLP-1/incretin obesity wave reshapes the treatment landscape — the pipeline being option value layered on top of the increasingly real commercial story. The capital story: an early-commercial-biopharma balance sheet — a growing-but-still-loss-making P&L funded primarily by equity, with modest or no debt and no shareholder returns — cash/equivalents/short-term investments ~$250-450M+ (replenished periodically via follow-on offerings and at-the-market sales, including around AHO de-risking), a net loss / cash burn ~$(150)-(280)M a year, a runway extending roughly into 2026-2027 (needing extension before sustained profitability, so further dilution likely — less acute than for a pre-revenue biotech since growing IMCIVREE revenue narrows the gap), possibly a modest term loan or convertible but leverage not the issue (runway/dilution is), no dividend and no buyback near-term, and ~60-70M+ shares outstanding (rising on financings + SBC), with the cash position and burn each quarter, the trajectory toward operating breakeven (as IMCIVREE revenue — especially post-AHO — scales over a relatively fixed cost base), the timing/size of any raise, and whether AHO's launch (or a partnership) accelerates the path to self-funding as watch items. At ~$40-80 per share on ~60-70M+ shares (~$2.5-5.5B equity, EV somewhat below net of cash) RYTM prices an increasingly real, fast-growing IMCIVREE franchise plus a large near-term expansion (AHO) plus pipeline option value, less the burn to profitability — no meaningful P/E yet (still loss-making); the framework is EV/revenue (a high multiple on a small-but-fast-growing rare-disease revenue base, the AHO ramp the key sensitivity) plus a pipeline option premium — versus rare-disease / specialty-biopharma names Ultragenyx (RARE), BridgeBio (BBIO), Crinetics (CRNX), Madrigal (MDGL), Insmed (INSM), Apellis (APLS), Argenx (ARGX), Amicus (FOLD), Vanda (VNDA), with Novo Nordisk and Eli Lilly (LLY) as the obesity-sector giants in the room (different populations, but the gravitational center). FY2026 base case: selected various aggregate ~$200-350M+ net product revenue (genetic obesity growing + early AHO contribution if approved) + ~$(150)-(280)M net loss + the AHO launch underway + ex-US expansion + bivamelagon advancing + the cash runway extended — strong revenue growth, still pre-profit; bull case: AHO approved on schedule and launching strongly into a sizeable, identifiable population, IMCIVREE revenue inflecting toward and past breakeven, ex-US ramping, bivamelagon (oral) delivering positive pivotal data (a major franchise extender), additional indications opening, and a re-rating toward a multi-billion 'scaling rare-disease franchise with a deep MC4R pipeline' valuation; bear case: an AHO regulatory setback or a disappointing launch, reimbursement pushback compressing price/access in a larger population, persistence/compliance issues capping the genetic-obesity base, bivamelagon or RM-718 failing in trials, a dilutive raise at a low price, GLP-1 encroachment on the broader narrative, and a de-rating. The thesis depends on the IMCIVREE-commercial pipeline (genetic-obesity uptake + the acquired-hypothalamic-obesity approval and launch + ex-US expansion + the path to profitability) plus the next-gen-MC4R pipeline (bivamelagon oral + RM-718 weekly + additional indications) plus disciplined cash management plus a reimbursement environment that supports rare-disease pricing plus David Meeker's execution of the rare-disease commercialization playbook.